The largest database of trusted experimental protocols

Nf light simoa assay advantage kit

Manufactured by Quanterix
Sourced in United States

The NF-Light Simoa Assay Advantage kit is a lab equipment product from Quanterix. It is designed to enable sensitive and precise measurement of analytes in biological samples.

Automatically generated - may contain errors

6 protocols using nf light simoa assay advantage kit

1

Quantifying Serum Neuronal and Glial Biomarkers

Check if the same lab product or an alternative is used in the 5 most similar protocols
Serum neurofilament light chain (sNfL) and serum glial fibrillary acidic protein
(sGFAP) were measured using Simoa assays16 (link)–18 (link, link) (Quanterix; NF light
Simoa Assay Advantage Kit, GFAP Simoa Discovery Kit). All samples were analyzed
for the same target (sNFL or sGFAP) at the same time point. Samples were thawed
and processed as recommended by the manufacturer and previously described.19 (link)
We assessed the intra-assay coefficient of variation (CV) by testing a
quality control serum sample in five replicates. A CV of lower than 10% had to
be achieved for valid analysis. Concentrations were calculated using
corresponding standard curves. The laboratory personnel were blinded for
clinical data.
+ Open protocol
+ Expand
2

Plasma NfL Quantification by Simoa

Check if the same lab product or an alternative is used in the 5 most similar protocols
Plasma NfL concentration was measured with NF-Light Simoa Assay Advantage kit, Quanterix.
+ Open protocol
+ Expand
3

Quantifying Plasma NFL Levels

Check if the same lab product or an alternative is used in the 5 most similar protocols
Plasma NFL concentration was measured with NF-Light Simoa Assay Advantage kit using Quanterix. The measurement was performed following the manufacturer’s instructions.
+ Open protocol
+ Expand
4

Biomarkers of Alzheimer's Disease in Chinese and UK Cohorts

Check if the same lab product or an alternative is used in the 5 most similar protocols
We measured the plasma level of sST2 in 613 individuals from Chinese_cohort_1 (n = 277 individuals with AD, n = 336 HCs); CSF level of sST2 in 86 individuals from the UKBBN cohort (n = 75 individuals with AD, n = 11 HCs); and the level of sST2 secreted by hCMEC/D3 cells using the Human ST2/IL-33 R Quantikine ELISA Kit (DST200; R&D Systems). The plasma levels of NfL (n = 154 individuals with AD, n = 135 HCs) and P-tau181 (n = 156 individuals with AD, n = 134 HCs) in individuals from Chinese_cohort_1 were measured by the Quanterix Accelerator Laboratory using the Quanterix NF-light SIMOA Assay Advantage Kit (103186) and P-Tau 181 Advantage V2 Kit (103714), respectively93 .
+ Open protocol
+ Expand
5

Quanterix NfL Protein Quantification

Check if the same lab product or an alternative is used in the 5 most similar protocols
Serum NfL concentrations (pg/mL) were determined by Quanterix Corp using the NF-Light Simoa Assay Advantage Kit (Quanterix Corp, MA, USA).
+ Open protocol
+ Expand
6

Longitudinal Biomarker Changes in Athletes

Check if the same lab product or an alternative is used in the 5 most similar protocols
Whole blood was collected (1) prior to non-contact conditioning (baseline); (2) at weeks 8, 12, 17, 21, 26, and 33 (Figure 1B). Blood draws during the regular season [Weeks 12, 17, 21, and 26 (end of season)] were done on Tuesday or Wednesday following game day. Week 33 was 7 weeks after the end of treatment. Twelve-hour fasted blood samples (22 ml whole blood) were collected via venipuncture into three vacutainer tubes [1 × 4.5 ml tri-sodium citrate, 1 × 7.5 ml powdered glass clot activator, 1 × 10 ml ethylene diamine tetra-acetic acid (EDTA)]. The tri-sodium citrate tube was stored on ice, packaged, and sent for analysis. Samples in the EDTA tube were centrifuged within 2 min of collection (1,714 g for 15 min). Samples in the clot activator tube were centrifuged 30 min post-collect (1,714 g for 15 min). Aliquots of red blood cells and plasma (EDTA tube) and serum (clot activator tube) were stored at−80C until analyzed. Serum neurofilament light (NfL) was quantified at baseline, Week 17, and Week 26 from serum using the NF-Light Simoa Assay Advantage Kit (Quanterix Corp, Billerica, MA). Other blood-based biomarkers included plasma fatty acids, interleukin-6 and tumor necrosis factor-alpha, all of which are thoroughly described in Mulllins et al. (43 (link)). For treatment effects in the present analyses, DHA and EPA data are also reported here.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!